EDITAS

Serial Number 86119062
606

Registration Progress

Application Filed
Nov 14, 2013
Under Examination
Jun 2, 2015
Approved for Publication
Apr 7, 2015
Published for Opposition
Apr 7, 2015
Registered

Basic Information

Serial Number
86119062
Filing Date
November 14, 2013
Published for Opposition
April 7, 2015
Abandonment Date
July 9, 2018
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Jul 9, 2018
Classes
005

Rights Holder

EDITAS MEDICINE, INC.

03
Address
300 Third Street, First Floor
Cambridge, MA 02142

Ownership History

Geneng, Inc.

Original Applicant
03
Waltham, MA

EDITAS MEDICINE, INC.

New Owner Before Publication #1
03
Cambridge, MA

EDITAS MEDICINE, INC.

Owner at Publication
03
Cambridge, MA

Legal Representation

Attorney
Timothy H. Hiebert

USPTO Deadlines

All Deadlines Cleared

All 1 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

50 events
Date Code Type Description
Jul 9, 2018 ABN6 S ABANDONMENT - NO USE STATEMENT FILED
Jul 9, 2018 MAB6 O ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Nov 7, 2017 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 6, 2017 EX5G S SOU EXTENSION 5 GRANTED
Oct 11, 2017 EEXT I SOU TEAS EXTENSION RECEIVED
Oct 11, 2017 EXT5 S SOU EXTENSION 5 FILED
May 27, 2017 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 25, 2017 EEXT I SOU TEAS EXTENSION RECEIVED
May 25, 2017 EXT4 S SOU EXTENSION 4 FILED
May 25, 2017 EX4G S SOU EXTENSION 4 GRANTED
Nov 8, 2016 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 7, 2016 EX3G S SOU EXTENSION 3 GRANTED
Oct 12, 2016 EEXT I SOU TEAS EXTENSION RECEIVED
Oct 12, 2016 EXT3 S SOU EXTENSION 3 FILED
Jul 9, 2016 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 8, 2016 EX2G S SOU EXTENSION 2 GRANTED
Jul 5, 2016 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jun 2, 2016 EEXT I SOU TEAS EXTENSION RECEIVED
Jun 2, 2016 EXT2 S SOU EXTENSION 2 FILED
Oct 8, 2015 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 6, 2015 EEXT I SOU TEAS EXTENSION RECEIVED
Oct 6, 2015 EXT1 S SOU EXTENSION 1 FILED
Oct 6, 2015 EX1G S SOU EXTENSION 1 GRANTED
Jun 2, 2015 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 7, 2015 PUBO A PUBLISHED FOR OPPOSITION
Apr 7, 2015 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 18, 2015 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 3, 2015 ALIE A ASSIGNED TO LIE
Mar 3, 2015 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 13, 2015 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 12, 2015 ERFR I TEAS REQUEST FOR RECONSIDERATION RECEIVED
Feb 12, 2015 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 12, 2015 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 2, 2014 CNFR R FINAL REFUSAL WRITTEN
Sep 2, 2014 GNFR O FINAL REFUSAL E-MAILED
Sep 2, 2014 GNFN O NOTIFICATION OF FINAL REFUSAL EMAILED
Aug 29, 2014 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 28, 2014 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 28, 2014 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 5, 2014 CPRA R PRIORITY ACTION WRITTEN
Mar 5, 2014 GPRA F PRIORITY ACTION E-MAILED
Mar 5, 2014 GPRN O NOTIFICATION OF PRIORITY ACTION E-MAILED
Mar 2, 2014 DOCK D ASSIGNED TO EXAMINER
Jan 2, 2014 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 2, 2014 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 2, 2014 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jan 2, 2014 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jan 1, 2014 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Nov 27, 2013 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 18, 2013 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
Pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological, hematologic and viral diseases and disorders; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the treatment of erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications, namely, antifungal preparations, dermatological preparations, smoking cessation preparations and tissue repair preparations
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005